AFP and neoplasm: Zhang et al. introduced the AFP and Tumor Shape Irregularity (ATSI) score, which evaluates the number of baseline conditions—AFP ≥ 400 ng/mL and initial tumor shape irregularity—met by a patient, based on a training set of 177 individuals who had poor prognoses with Atezo + Bev treatment [96].